Uncategorized
Full-Spectrum CBD Drug for Autism Spectrum Disorder Poised for Phase 2 Clinical Trials in the US
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioral symptoms associated with autism spectrum disorder (ASD).